Johnson & Johnson (J&J) has ended its contract pharmacy restrictions for covered entities in Arkansas, making the New Jersey-based pharmaceutical [...] …
Articles by : Bella Czajkowski, National Correspondent
Drugmaker Kedrion Biopharma has posted a refund notice to 340B providers, and Mylan notified covered entities of National Drug Code [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Six national hospital associations recently urged the Supreme Court to correct what they called the Department of Health and Human [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Two weeks after publishing an opinion piece that called for increased 340B program oversight and provider transparency, JAMA issued a [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The Health Resources and Services Administration (HRSA) has requested public comment on how petitioners file their initial claims in the [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The Health Resources and Services Administration (HRSA) held a webinar yesterday to guide hospitals through their annual 340B recertification period, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A recent opinion piece published in JAMA is calling for significant reforms to the 340B program, including more provider transparency, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
With the annual 340B hospital recertification period occurring Aug. 12 to Sept. 9, the Health Resources and Services Administration’s (HRSA’s) [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Just days after a federal court in Mississippi denied Novartis’ attempt to block the state’s 340B contract pharmacy access law, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SK Life Science issued a refund notice for an epilepsy drug following a 340B price ceiling recalculation. Multiple drug manufacturers [...] …
